Zobrazeno 1 - 10
of 12
pro vyhledávání: '"M Carrasco-Gomariz"'
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Eribulin is used, as monotherapy, in the secondline treatment of locally advanced or metastatic breast cancer (mBC) in patients who have previously received an anthracycline and a taxane or these are contraindicated. ESMO-MC
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Myelotoxicity is a main concern when treating cancer patients with chemotherapy. It compromises safety but also the dose intensity received by the patient and thus treatment prognosis. One study (Katsifis, 2002) showed that
Autor:
M Carrasco Gomariz, N Martinez Casanova, M Lopez Martinez, A Cahue Urrutia, A Madrid Paredes, S Guijarro Herrera
Publikováno v:
Eur J Hosp Pharm
Background Proton pump inhibitors (PPIs) are often used inappropriately, without an indication, or for longer durations than recommended. Deprescribing is defined as the reduction, withdrawal or discontinuation of inappropriate medication. We aimed t
Autor:
Rocío López-Sepúlveda, M Rodríguez Goicoechea, ME Espínola García, S Anaya Ordóñez, F Artime Rodríguez, M Carrasco Gomariz, Martín Sances, J Cabeza Barrera, MA García Lirola
Publikováno v:
European Journal of Hospital Pharmacy. 23:A4.2-A4
Background In some regions, the pharmaceutical services at nursing homes are held by pharmacists from hospitals in the public network. Purpose To determine the impact of medicines reconciliation on the prevalence of potentially inappropriate medicine
Autor:
M Carrasco Gomariz, SI Garcia Dominguez, A Jiménez Morales, MA Calleja Hernández, M Ferrit Martin, T Simon Sanchez
Publikováno v:
European Journal of Hospital Pharmacy. 23:A110.1-A110
Background The process of distributing drugs to hospitalised patients is complex, which is why it is necessary to establish improvement strategies in hospitals to ensure patient safety, monitoring every point in the process of the distribution of dru
Autor:
M Carrasco Gomariz, Rocío López-Sepúlveda, N Martinez Casanova, M Rodríguez Goicoechea, F Artime Rodríguez, I. Vallejo Rodríguez, J Cabeza Barrera, MA Calleja Hernández
Publikováno v:
European Journal of Hospital Pharmacy. 23:A3.2-A4
Background The switch from the intravenous (IV) formulation to the subcutaneous (SC) formulation of abatacept (ABA) had been analysed in clinical trials but there are few data regarding the effectiveness and safety of the SC formulation in clinical p
Autor:
M Carrasco Gomariz, F Ibañez Lopez, M Ferrit Martin, N Albina Olalla, MA Calleja Hernández, L Gutiérrez Zúñiga, Caparrós Romero
Publikováno v:
European Journal of Hospital Pharmacy. 23:A134.2-A135
Background The effectiveness and safety of drugs for the treatment of inflammatory rheumatic diseases (IRD) are well known. Patients treated with disease modifying antirheumatic drugs (DMARDs) and anti-tumour necrosis factor alpha (TNF-alpha) drugs d
Autor:
A Jimenez-Morales, M Carrasco Gomariz, Miguel Ángel Calleja-Hernández, CM Valencia-Soto, Marisa Cañadas-Garre, J Pérez-Morales
Publikováno v:
European Journal of Hospital Pharmacy. 23:A175.1-A175
Background Respiratory syncytial virus (RSV) is a common infection among children, with nearly 70% of children affected by 2 years, 22% developing symptomatology and 2–5% requiring hospitalisation. National Clinical Practice guidelines and Paediatr
Autor:
Miguel Ángel Calleja-Hernández, M Carrasco-Gomariz, C Valencia-Soto, F Artime-Rodriguez-Hermida, M Ferrit-Martin, N Martinez-Casanova
Publikováno v:
European Journal of Hospital Pharmacy. 23:A86.1-A86
Background Biological agents are used to treat rheumatic diseases. Patients are initially treated at the recommended dose according to the results of clinical trials but there is no current consensus on what attitude to take following remission. The
Autor:
CM Valencia Soto, M Rodriguez-Goicoechea, A Jimenez-Morales, F Artime-Rodriguez-Hermida, M Carrasco-Gomariz
Publikováno v:
European Journal of Hospital Pharmacy. 22:A29.3-A30
Background Natalizumab is indicated in relapsing-remitting multiple sclerosis (RRMS) that remains highly active despite treatment with interferon B and glatiramer acetate, and in rapidly evolving severe RRMS. Purpose To analyse the effectiveness, saf